AI Summary
This article discusses the results of a phase 1 trial in healthy adults that examined the humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine. The study aimed to characterize the immune response generated by the vaccine, which is important for assessing its potential efficacy and safety for use in preventing cytomegalovirus infections. The findings of this trial could provide valuable insights into the development of future vaccines for cytomegalovirus and other infectious diseases.